Skip to main content
LBRX
NASDAQ Life Sciences

LB Pharmaceuticals Registers Over 4.7M Shares for Resale by Selling Stockholders

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$26.94
Mkt Cap
$681.558M
52W Low
$13.36
52W High
$27.55
52W Position info
102% above low
Off High info
2.2% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

LBRX has more than doubled off its 52-week low of $13.36 on elevated volume (1.8× avg).

Summary

LB Pharmaceuticals filed an S-1 registration statement to allow certain selling stockholders to resell up to 4.78 million shares of common stock, including shares from a recent private placement, potentially creating significant market overhang.


Key Events · Financing and Capital Events · LBRX

  • Resale Registration Filed

    Registers 4,778,491 shares of common stock for resale by selling stockholders.

  • Significant Market Overhang

    The registered shares represent approximately 16.7% of the company's outstanding common stock, indicating substantial potential selling pressure.

  • Follows Private Placement

    Shares are primarily from a $100 million private placement in February 2026, making them eligible for public trading.

  • No Direct Company Proceeds

    LB Pharmaceuticals will not receive any proceeds from these sales, except for nominal exercise prices from pre-funded warrants.


Analysis · LBRX · Life Sciences

This S-1 filing registers approximately 4.78 million shares for resale by selling stockholders, representing about 16.7% of the company's outstanding common stock. These shares primarily stem from a $100 million private placement completed in February 2026, which was previously disclosed in an 8-K filing on March 26, 2026. While the company will not receive proceeds from these sales (except for nominal warrant exercise prices), the registration makes these shares eligible for trading, introducing a substantial potential selling overhang on the stock. The selling stockholders acquired these shares at $21.17, below the current market price of $26.94, suggesting they may seek to monetize their positions, especially as the stock is trading near its 52-week high. This event follows a period of insider accumulation, presenting a mixed signal to investors.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LBRX was trading at $26.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $681.6M. The 52-week trading range was $13.36 to $27.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LBRX - Latest Insights

LBRX
Nov 05, 2026, 8:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $38.09
Real-time Price: $38.85 info
Change: +$0.760 (+2%) info
Market Cap: $1.257B info
LBRX
Nov 05, 2026, 4:32 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $38.09
Real-time Price: $38.85 info
Change: +$0.760 (+2%) info
Market Cap: $1.257B info
LBRX
Nov 05, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.09
Real-time Price: $38.85 info
Change: +$0.760 (+2%) info
Market Cap: $1.257B info
LBRX
Oct 01, 2026, 4:05 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $37.28
Real-time Price: $38.85 info
Change: +$1.57 (+4%) info
Market Cap: $1.257B info
LBRX
Aug 11, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $46.76
Real-time Price: $38.85 info
Change: -$7.91 (-17%) info
Market Cap: $1.257B info